6-(ethylthio)pyridin-3-amine | 52025-15-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 6-(ethylthio)pyridin-3-amine
• 英文别名: 6-(Ethylsulfanyl)pyridin-3-amine；6-ethylsulfanylpyridin-3-amine
• CAS: 52025-15-7
• 化学式: C₇H₁₀N₂S
• mdl: MFCD10007807
• 分子量: 154.236
• InChiKey: QPNSNROGWGPVOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(ethylthio)pyridin-3-amine 在 ruthenium trichloride 、 palladium diacetate 三乙烯二胺 、 sodium periodate 作用下， 以 甲醇 、 乙醇 、 水 、 乙腈 为溶剂， 反应 18.5h， 生成 2-((R)-4-((5-(ethylsulfonyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl)-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl)-5-fluoro-N-((S)-1-(4-methoxyphenyl)ethyl)benzamide
  参考文献：
  名称：

  [EN] GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
  [FR] MIMÉTIQUES DE GLUCOCORTICOÏDES, LEURS PROCÉDÉS DE FABRICATION, DES COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2009149139A8
• 作为产物：
  描述：

  2-乙硫基-5-硝基吡啶 在 盐酸 、 tin 作用下， 生成 6-(ethylthio)pyridin-3-amine
  参考文献：
  名称：

  Forrest; Walker, Journal of the Chemical Society, <1948> 1939, 1944

  摘要：

  DOI：

文献信息

• [EN] POLYCYCLIC COMPOUNDS AS ROR-GAMMA MODULATORS<br/>[FR] COMPOSÉS POLYCYCLIQUES EN TANT QUE MODULATEURS DE ROR-GAMMA
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2018011747A1

  公开（公告）日：2018-01-18

  The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.

  本发明提供了调节RORγ的化合物，以及它们用于治疗由RORγ介导的疾病或症状。此外，本发明涉及制备这些化合物的过程，它们的互变异构体形式，参与其合成的新型中间体，它们的药用盐，使用这些化合物的方法以及含有它们的药物组合物。
• .omega.-(3-pyridyl)alkenamide derivatives and anti-allergenic
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04778796A1

  公开（公告）日：1988-10-18

  Compounds of the formula: ##STR1## wherein X is alkylene or --(CR.sub.6 .dbd.CR.sub.7).sub.r -- wherein R.sub.6 is H, alkyl or phenyl, R.sub.7 is H, alkyl, cyano or phenyl, and r is 1 or 2; A is alkylene or alkylene interrupted by at least one double bond; R.sub.1 is H, halogen, alkyl, alkoxy, alkylthio, cycloalkyloxy, cycloalkylthio, alkoxycarbonyl, carboxy, phenyl, phenoxy, phenylthio, 3-pyridyloxy or 3-pyridylthio; R.sub.2 is H, hydroxy, alkanoyloxy or alkoxycarbonyloxy, or adjacent R.sub.1 and R.sub.2 may combine to form tetramethylene or --CH.sub.2 OCR.sub.8 R.sub.9 O-- (R.sub.8 and R.sub.9 are alkyl); R.sub.3 is H, alkyl or hydroxyalkyl; R.sub.4 is H or alkyl; R.sub.5 is phenyl, heteroaryl or --(CH.sub.2).sub.m --CHR.sub.10 R.sub.11 (R.sub.10 is H or phenyl, R.sub.11 is phenyl or pyridyl and m is 0 to 2); p is 0 or 1; and q is 2 or 3; the phenyl group or moiety being optionally substituted, and a salt thereof, process for the preparation thereof, and pharmaceutical composition containing the same. Said compounds and salts thereof show excellent antiallergic activity mainly through 5-lipoxygenase inhibiting activity, antihistamine activity and/or inhibitory activity against chemical mediator release and useful for treatment of allergic diseases.

  该公式化合物为：##STR1## 其中X为烷基或--(CR.sub.6.dbd.CR.sub.7).sub.r --，其中R.sub.6为H、烷基或苯基，R.sub.7为H、烷基、氰基或苯基，r为1或2；A为烷基或至少有一个双键的烷基；R.sub.1为H、卤素、烷基、烷氧基、烷硫基、环烷氧基、环烷硫基、烷氧羰基、羧基、苯基、苯氧基、苯硫基、3-吡啶氧基或3-吡啶硫基；R.sub.2为H、羟基、烷酰氧基或烷氧羰酰氧基，或相邻的R.sub.1和R.sub.2可以结合形成四亚甲基或--CH.sub.2 OCR.sub.8 R.sub.9 O--（其中R.sub.8和R.sub.9为烷基）；R.sub.3为H、烷基或羟基烷基；R.sub.4为H或烷基；R.sub.5为苯基、杂环芳基或--(CH.sub.2).sub.m --CHR.sub.10 R.sub.11（其中R.sub.10为H或苯基，R.sub.11为苯基或吡啶基，m为0到2）；p为0或1；q为2或3；苯基或基团可选择性地被取代；以及其盐、制备方法和含有它的药物组成物。所述化合物及其盐主要通过5-脂氧酶抑制活性、抗组胺活性和/或化学介质释放抑制活性表现出优异的抗过敏活性，并用于治疗过敏性疾病。
• Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
  申请人：Harcken Christian

  公开号：US20090325988A1

  公开（公告）日：2009-12-31

  Compounds of Formula (I) wherein R 1 , R 2 , X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  化合物的公式（I），其中R1，R2，X和Y的定义如本文所述，或其互变异构体，光学异构体，前药，共晶体或盐；含有这些化合物的药物组合物，以及使用这些化合物调节糖皮质激素受体功能的方法，治疗由糖皮质激素受体功能介导或以炎症，过敏或增殖过程为特征的疾病状态或病情的方法。
• Expedient Synthesis of Alkyl and Aryl Thioethers Using Xanthates as Thiol-Free Reagents
  作者：Jinli Nie、Ziqing He、Sijie Xie、Yibiao Li、Runfa He、Lu Chen、Xiai Luo

  DOI：10.3390/molecules29112485

  日期：——

  synthesizing dialkyl or alkyl aryl thioether derivatives using odorless, stable, low-cost ROCS2K as a thiol surrogate. This transformation offers a broad substrate scope and good functional group tolerance with excellent selectivity. The reaction likely proceeds via xanthate intermediates, which can be readily generated via the nucleophilic substitution of alkyl halides or aryl halides with ROCS2K under

  硫醚在医药和有机合成领域至关重要，但大多数合成烷基硫醚的方法都采用有恶臭的硫醇作为起始原料或产生副产物。另外，大多数硫醇对空气敏感，在大气条件下很容易氧化生成二硫化物；因此，需要一种新的硫醚合成方法。本文报道了一种简单、有效、绿色的方法，使用无味、稳定、低成本的ROCS2K作为硫醇替代物合成二烷基或烷基芳基硫醚衍生物。这种转化提供了广泛的底物范围和良好的官能团耐受性以及出色的选择性。该反应可能通过黄原酸酯中间体进行，黄原酸酯中间体可以通过在无过渡金属和无碱条件下用 ROCS2K 亲核取代烷基卤或芳基卤轻松生成。
• Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides
  作者：Yoshinori Nishikawa、Tokuhiko Shindo、Katsumi Ishii、Hideo Nakamura、Tatsuya Kon、Hitoshi Uno

  DOI：10.1021/jm00123a012

  日期：1989.3

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.